CMTP

Resource Center

Browse industry research articles, publications, and other important resources.

Stakeholder Engagement resources

Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, R. B., Adib, G., Adler, R. A., Akesson, K. E., Alexander, I. M., Amenta, K. C., et al. Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. Journal of Bone and Mineral Research, September 2019. https://asbmr.onlinelibrary.wiley.com/doi/10.1002/jbmr.3877
Engaging patients, clinicians, and the community in a Clinical Data Research Network: Lessons learned from the CAPriCORN
Tambor E, Shalowitz M, Harrington, JM, et al. Engaging patients, clinicians, and the community in a Clinical Data Research Network: Lessons learned from the CAPriCORN CDRN. Learn Health Sys. 2019;e10079. https://doi.org/10.1002/lrh2.10079
Practical Guidance for Involving Stakeholders in Health Research (December 2018)
Concannon, T.W., Grant, S, Welch, V, Petkovic, J, Selby, J, Crowe, S, Synnot, A, Greer-Smith, R, Mayo-Wilson, E, Tambor, E, Tugwell, P. Practical Guidance for Involving Stakeholders in Health Research. Journal of General Internal Medicine, 2018,1-6. https://doi.org/10.1007/s11606-018-4738-6
Stakeholder Engagement in Comparative Effectiveness Research: How Will We Measure Success? (Sept 2012)
Lavallee DC, Williams CJ, Deverka PD, Tambor ES. Stakeholder engagement in comparative effectiveness research: how will we measure success? J Comp Eff Res. 2012;1(5):397-407. doi: 10.2217/CER.12.44
ATHENA Breast Health Network
This partnership seeks to revolutionize breast cancer care and molecular diagnostics by merging research, technology, financing and health care delivery to reduce the time needed to translate research findings into patient care. CMTP led the Biomarker Stakeholder Advisory Group, developed a business plan for sustainable partnerships between ATHENA and other health care stakeholders, and advised on proposed CER projects to identify best treatments for women with low, medium and high-risk breast tumors.